 Robert MacLaren
Concepts (400)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Critical Illness | 40 | 2023 | 643 | 6.200 |
Why?
| | Intensive Care Units | 38 | 2023 | 619 | 5.450 |
Why?
| | Peptic Ulcer | 8 | 2023 | 14 | 3.990 |
Why?
| | Enteral Nutrition | 13 | 2023 | 157 | 3.160 |
Why?
| | Critical Care | 21 | 2020 | 474 | 3.130 |
Why?
| | Histamine H2 Antagonists | 8 | 2021 | 29 | 2.940 |
Why?
| | Hypnotics and Sedatives | 11 | 2019 | 134 | 2.880 |
Why?
| | Dexmedetomidine | 9 | 2019 | 45 | 2.840 |
Why?
| | Proton Pump Inhibitors | 7 | 2023 | 96 | 2.650 |
Why?
| | Pharmacy Service, Hospital | 9 | 2020 | 84 | 2.510 |
Why?
| | Pharmacists | 9 | 2020 | 236 | 2.130 |
Why?
| | Gastric Emptying | 8 | 2017 | 40 | 2.040 |
Why?
| | Gastrointestinal Hemorrhage | 5 | 2021 | 102 | 1.860 |
Why?
| | Shock, Septic | 4 | 2022 | 185 | 1.600 |
Why?
| | Substance Withdrawal Syndrome | 4 | 2022 | 159 | 1.600 |
Why?
| | Anticoagulants | 12 | 2023 | 547 | 1.550 |
Why?
| | Epoprostenol | 2 | 2023 | 133 | 1.460 |
Why?
| | Heparin | 7 | 2023 | 222 | 1.430 |
Why?
| | Vasopressins | 4 | 2022 | 56 | 1.210 |
Why?
| | Sepsis | 7 | 2023 | 508 | 1.200 |
Why?
| | Retrospective Studies | 35 | 2023 | 12544 | 1.150 |
Why?
| | Pneumonia | 5 | 2022 | 568 | 1.130 |
Why?
| | Lorazepam | 4 | 2014 | 23 | 1.130 |
Why?
| | Hemorrhage | 9 | 2021 | 618 | 1.130 |
Why?
| | Metoclopramide | 6 | 2010 | 16 | 1.120 |
Why?
| | Factor VIIa | 5 | 2016 | 36 | 1.020 |
Why?
| | Stress, Physiological | 4 | 2021 | 378 | 1.000 |
Why?
| | Thromboembolism | 2 | 2020 | 94 | 0.990 |
Why?
| | Adult | 42 | 2023 | 30608 | 0.980 |
Why?
| | Vasoconstrictor Agents | 5 | 2023 | 112 | 0.980 |
Why?
| | Thrombelastography | 2 | 2023 | 175 | 0.980 |
Why?
| | Recombinant Proteins | 13 | 2023 | 1233 | 0.960 |
Why?
| | Gastrointestinal Agents | 5 | 2010 | 60 | 0.960 |
Why?
| | Propofol | 5 | 2019 | 43 | 0.960 |
Why?
| | Proton Pumps | 2 | 2014 | 8 | 0.950 |
Why?
| | Humans | 97 | 2023 | 114937 | 0.940 |
Why?
| | Ulcer | 1 | 2023 | 28 | 0.870 |
Why?
| | Alcoholism | 2 | 2022 | 715 | 0.830 |
Why?
| | Blood Coagulation Factors | 3 | 2020 | 44 | 0.790 |
Why?
| | Midazolam | 3 | 2013 | 43 | 0.780 |
Why?
| | Hypothermia, Induced | 2 | 2013 | 67 | 0.770 |
Why?
| | Hypotension | 2 | 2022 | 113 | 0.750 |
Why?
| | Oseltamivir | 1 | 2021 | 11 | 0.750 |
Why?
| | Analgesia | 2 | 2018 | 82 | 0.740 |
Why?
| | Anti-Ulcer Agents | 3 | 2017 | 16 | 0.740 |
Why?
| | Venous Thromboembolism | 2 | 2021 | 231 | 0.710 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2022 | 191 | 0.710 |
Why?
| | Burns | 2 | 2018 | 237 | 0.700 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2023 | 240 | 0.700 |
Why?
| | Conscious Sedation | 2 | 2013 | 79 | 0.680 |
Why?
| | Acute Kidney Injury | 4 | 2023 | 638 | 0.680 |
Why?
| | Esomeprazole | 1 | 2018 | 6 | 0.650 |
Why?
| | Fibrinolytic Agents | 3 | 2016 | 233 | 0.640 |
Why?
| | Pulmonary Embolism | 1 | 2021 | 183 | 0.640 |
Why?
| | Staphylococcal Infections | 1 | 2022 | 336 | 0.630 |
Why?
| | Fluid Therapy | 3 | 2023 | 122 | 0.630 |
Why?
| | Phenytoin | 1 | 2017 | 13 | 0.600 |
Why?
| | Erythromycin | 4 | 2010 | 24 | 0.580 |
Why?
| | Ethanol | 3 | 2022 | 548 | 0.580 |
Why?
| | Albumins | 1 | 2017 | 89 | 0.570 |
Why?
| | Ketamine | 1 | 2018 | 92 | 0.570 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 2 | 2015 | 24 | 0.560 |
Why?
| | Blood Coagulation Disorders | 2 | 2016 | 192 | 0.560 |
Why?
| | Middle Aged | 33 | 2019 | 26806 | 0.550 |
Why?
| | Plasma | 2 | 2016 | 210 | 0.540 |
Why?
| | Anticonvulsants | 2 | 2017 | 178 | 0.530 |
Why?
| | Blood Coagulation | 2 | 2007 | 217 | 0.500 |
Why?
| | Hydrocortisone | 1 | 2017 | 270 | 0.500 |
Why?
| | Community-Acquired Infections | 2 | 2014 | 141 | 0.500 |
Why?
| | Influenza, Human | 1 | 2021 | 546 | 0.500 |
Why?
| | Male | 42 | 2021 | 55663 | 0.490 |
Why?
| | Glial Cell Line-Derived Neurotrophic Factor | 1 | 2015 | 16 | 0.490 |
Why?
| | Acetaminophen | 5 | 2010 | 238 | 0.490 |
Why?
| | Nerve Growth Factor | 1 | 2015 | 27 | 0.490 |
Why?
| | Nitric Oxide | 1 | 2020 | 827 | 0.480 |
Why?
| | Stress, Psychological | 2 | 2018 | 945 | 0.480 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 2014 | 25 | 0.480 |
Why?
| | Drug Monitoring | 3 | 2017 | 184 | 0.470 |
Why?
| | Stomach Diseases | 2 | 2011 | 19 | 0.470 |
Why?
| | Hippocampus | 1 | 2018 | 696 | 0.470 |
Why?
| | Randomized Controlled Trials as Topic | 7 | 2023 | 1215 | 0.460 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2015 | 106 | 0.460 |
Why?
| | Erythropoietin | 2 | 2005 | 72 | 0.460 |
Why?
| | Epinephrine | 1 | 2015 | 167 | 0.450 |
Why?
| | Partial Thromboplastin Time | 3 | 2023 | 51 | 0.450 |
Why?
| | Polyvinyl Chloride | 1 | 2013 | 5 | 0.440 |
Why?
| | Hemodynamics | 2 | 2019 | 1014 | 0.440 |
Why?
| | Professional Role | 4 | 2020 | 152 | 0.440 |
Why?
| | Voriconazole | 3 | 2019 | 24 | 0.430 |
Why?
| | Female | 37 | 2021 | 59581 | 0.420 |
Why?
| | APACHE | 2 | 2010 | 58 | 0.420 |
Why?
| | Pain | 1 | 2018 | 710 | 0.410 |
Why?
| | Sodium Chloride | 1 | 2013 | 136 | 0.410 |
Why?
| | Cross Infection | 4 | 2008 | 197 | 0.410 |
Why?
| | Gastrointestinal Microbiome | 1 | 2018 | 502 | 0.410 |
Why?
| | Mental Recall | 1 | 2013 | 170 | 0.410 |
Why?
| | Pseudomonas Infections | 4 | 2010 | 185 | 0.400 |
Why?
| | Drug Resistance | 2 | 2011 | 158 | 0.390 |
Why?
| | Cohort Studies | 8 | 2023 | 4903 | 0.390 |
Why?
| | Gastrointestinal Hormones | 1 | 2011 | 8 | 0.390 |
Why?
| | Hirudins | 4 | 2023 | 46 | 0.390 |
Why?
| | Ghrelin | 1 | 2011 | 33 | 0.380 |
Why?
| | Heparin, Low-Molecular-Weight | 2 | 2023 | 27 | 0.380 |
Why?
| | Aged | 20 | 2021 | 19122 | 0.380 |
Why?
| | Cisapride | 2 | 2001 | 5 | 0.370 |
Why?
| | Neuromuscular Blocking Agents | 1 | 2011 | 24 | 0.370 |
Why?
| | Neuromuscular Blockade | 1 | 2011 | 22 | 0.370 |
Why?
| | Double-Blind Method | 6 | 2015 | 1663 | 0.370 |
Why?
| | Coagulants | 2 | 2008 | 12 | 0.360 |
Why?
| | Infusions, Intravenous | 6 | 2016 | 372 | 0.360 |
Why?
| | Factor VII | 2 | 2007 | 26 | 0.350 |
Why?
| | Analgesics, Non-Narcotic | 2 | 2010 | 117 | 0.350 |
Why?
| | Factor Xa Inhibitors | 2 | 2023 | 138 | 0.350 |
Why?
| | Drug Therapy, Combination | 6 | 2017 | 954 | 0.350 |
Why?
| | Tachyphylaxis | 1 | 2009 | 1 | 0.350 |
Why?
| | Pharmaceutical Vehicles | 1 | 2009 | 11 | 0.340 |
Why?
| | Factor Xa | 2 | 2021 | 32 | 0.340 |
Why?
| | Heart Arrest | 1 | 2013 | 289 | 0.340 |
Why?
| | Propylene Glycol | 1 | 2009 | 9 | 0.340 |
Why?
| | Respiration, Artificial | 6 | 2019 | 526 | 0.340 |
Why?
| | Protein C | 1 | 2010 | 45 | 0.340 |
Why?
| | Pseudomonas aeruginosa | 4 | 2010 | 299 | 0.340 |
Why?
| | Attitude of Health Personnel | 2 | 2014 | 978 | 0.330 |
Why?
| | Extravasation of Diagnostic and Therapeutic Materials | 2 | 2023 | 14 | 0.330 |
Why?
| | Bradycardia | 3 | 2021 | 48 | 0.320 |
Why?
| | Hemofiltration | 3 | 2017 | 31 | 0.310 |
Why?
| | Lung Diseases | 2 | 2007 | 703 | 0.310 |
Why?
| | Drug Resistance, Multiple, Bacterial | 3 | 2005 | 63 | 0.310 |
Why?
| | Immune System | 1 | 2009 | 173 | 0.310 |
Why?
| | Antifungal Agents | 3 | 2019 | 129 | 0.300 |
Why?
| | Anesthesia | 1 | 2009 | 117 | 0.300 |
Why?
| | Treatment Outcome | 10 | 2021 | 9105 | 0.300 |
Why?
| | Nursing Audit | 1 | 2007 | 6 | 0.300 |
Why?
| | Forms and Records Control | 1 | 2007 | 22 | 0.290 |
Why?
| | Peptide Fragments | 3 | 2023 | 668 | 0.290 |
Why?
| | Physicians | 2 | 2013 | 772 | 0.290 |
Why?
| | Anti-Bacterial Agents | 5 | 2022 | 1477 | 0.290 |
Why?
| | Evidence-Based Medicine | 3 | 2008 | 675 | 0.280 |
Why?
| | Triazoles | 2 | 2019 | 130 | 0.280 |
Why?
| | Hemostatics | 1 | 2007 | 47 | 0.280 |
Why?
| | Antifibrinolytic Agents | 1 | 2007 | 50 | 0.280 |
Why?
| | Anesthetics | 1 | 2007 | 54 | 0.280 |
Why?
| | Bacterial Infections | 1 | 2008 | 219 | 0.280 |
Why?
| | Risk Management | 1 | 2007 | 89 | 0.270 |
Why?
| | Dopamine Antagonists | 2 | 2008 | 22 | 0.270 |
Why?
| | Glutamine | 1 | 2007 | 91 | 0.270 |
Why?
| | Clinical Pharmacy Information Systems | 1 | 2006 | 6 | 0.270 |
Why?
| | Models, Economic | 1 | 2006 | 48 | 0.270 |
Why?
| | Respiration | 1 | 2007 | 180 | 0.270 |
Why?
| | Practice Patterns, Physicians' | 1 | 2014 | 1177 | 0.260 |
Why?
| | Surveys and Questionnaires | 5 | 2020 | 4635 | 0.260 |
Why?
| | Factor VII Deficiency | 1 | 2005 | 4 | 0.260 |
Why?
| | Analgesics, Opioid | 2 | 2018 | 773 | 0.260 |
Why?
| | Intubation, Gastrointestinal | 2 | 2008 | 53 | 0.250 |
Why?
| | Risk Factors | 8 | 2023 | 8637 | 0.250 |
Why?
| | Prospective Studies | 7 | 2022 | 6218 | 0.250 |
Why?
| | Hydrogen-Ion Concentration | 4 | 2014 | 512 | 0.230 |
Why?
| | Antidotes | 2 | 2016 | 135 | 0.230 |
Why?
| | Drug Interactions | 2 | 2023 | 347 | 0.230 |
Why?
| | Anemia | 1 | 2005 | 144 | 0.220 |
Why?
| | Regression Analysis | 3 | 2017 | 947 | 0.220 |
Why?
| | Clostridium Infections | 2 | 2014 | 56 | 0.220 |
Why?
| | Fentanyl | 2 | 2018 | 66 | 0.220 |
Why?
| | Erythrocyte Transfusion | 1 | 2005 | 186 | 0.210 |
Why?
| | Patients' Rooms | 1 | 2022 | 13 | 0.210 |
Why?
| | Saline Solution, Hypertonic | 1 | 2023 | 53 | 0.210 |
Why?
| | Microbial Sensitivity Tests | 3 | 2018 | 301 | 0.210 |
Why?
| | Biological Availability | 1 | 2023 | 119 | 0.210 |
Why?
| | Predictive Value of Tests | 3 | 2017 | 1801 | 0.210 |
Why?
| | Time Factors | 8 | 2018 | 6125 | 0.210 |
Why?
| | Warfarin | 2 | 2007 | 135 | 0.210 |
Why?
| | Colorado | 7 | 2017 | 4091 | 0.200 |
Why?
| | Myocardial Infarction | 1 | 2009 | 929 | 0.200 |
Why?
| | Renal Replacement Therapy | 2 | 2015 | 66 | 0.200 |
Why?
| | Antacids | 1 | 2001 | 15 | 0.200 |
Why?
| | Minnesota | 1 | 2022 | 134 | 0.200 |
Why?
| | Health Care Costs | 1 | 2005 | 380 | 0.190 |
Why?
| | Antiemetics | 2 | 2010 | 32 | 0.190 |
Why?
| | Anti-Infective Agents | 1 | 2004 | 225 | 0.190 |
Why?
| | Incidence | 3 | 2022 | 2316 | 0.190 |
Why?
| | Length of Stay | 4 | 2014 | 949 | 0.190 |
Why?
| | Norepinephrine | 1 | 2022 | 207 | 0.190 |
Why?
| | Decision Support Techniques | 3 | 2014 | 352 | 0.190 |
Why?
| | Prothrombin | 1 | 2021 | 22 | 0.190 |
Why?
| | Inflammation | 1 | 2011 | 2485 | 0.180 |
Why?
| | Catheters | 1 | 2021 | 65 | 0.180 |
Why?
| | Pharmaceutical Preparations | 1 | 2023 | 169 | 0.180 |
Why?
| | Resuscitation | 1 | 2023 | 247 | 0.180 |
Why?
| | Thrombolytic Therapy | 1 | 2021 | 117 | 0.180 |
Why?
| | Ischemia | 1 | 2023 | 362 | 0.170 |
Why?
| | Invasive Fungal Infections | 1 | 2019 | 10 | 0.160 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2014 | 1856 | 0.160 |
Why?
| | Adrenal Cortex Hormones | 1 | 2002 | 499 | 0.160 |
Why?
| | Cross-Sectional Studies | 3 | 2020 | 4407 | 0.160 |
Why?
| | Restraint, Physical | 1 | 2018 | 67 | 0.160 |
Why?
| | Patient Care | 1 | 2019 | 103 | 0.160 |
Why?
| | Oxygen | 1 | 2023 | 853 | 0.150 |
Why?
| | Nitriles | 1 | 2019 | 151 | 0.150 |
Why?
| | Patient Satisfaction | 1 | 2022 | 583 | 0.150 |
Why?
| | Hospital Costs | 2 | 2009 | 103 | 0.150 |
Why?
| | Administration, Inhalation | 1 | 2020 | 642 | 0.150 |
Why?
| | Vasoconstriction | 2 | 2023 | 186 | 0.150 |
Why?
| | Random Allocation | 1 | 2018 | 335 | 0.150 |
Why?
| | Critical Care Nursing | 1 | 2018 | 29 | 0.150 |
Why?
| | Hepatorenal Syndrome | 2 | 2009 | 14 | 0.150 |
Why?
| | Anesthetics, Intravenous | 1 | 1997 | 28 | 0.150 |
Why?
| | RNA, Bacterial | 1 | 2018 | 174 | 0.150 |
Why?
| | Fat Emulsions, Intravenous | 1 | 1997 | 27 | 0.150 |
Why?
| | Pharmacoepidemiology | 2 | 2014 | 20 | 0.150 |
Why?
| | Vancomycin | 1 | 2018 | 75 | 0.150 |
Why?
| | Area Under Curve | 2 | 2008 | 275 | 0.140 |
Why?
| | Cost-Benefit Analysis | 2 | 2014 | 546 | 0.140 |
Why?
| | Sucralfate | 1 | 2017 | 4 | 0.140 |
Why?
| | Piracetam | 1 | 2017 | 14 | 0.140 |
Why?
| | Stomach Ulcer | 1 | 2017 | 9 | 0.140 |
Why?
| | Drug Compounding | 2 | 2017 | 89 | 0.140 |
Why?
| | United States | 7 | 2018 | 12211 | 0.140 |
Why?
| | Statistics, Nonparametric | 2 | 2016 | 387 | 0.140 |
Why?
| | Analgesics | 1 | 2018 | 158 | 0.140 |
Why?
| | International Normalized Ratio | 1 | 2016 | 45 | 0.140 |
Why?
| | Intracranial Hemorrhages | 1 | 2017 | 76 | 0.140 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2018 | 486 | 0.140 |
Why?
| | Thiocyanates | 1 | 2016 | 29 | 0.140 |
Why?
| | Nitroprusside | 1 | 2016 | 64 | 0.140 |
Why?
| | Thiosulfates | 1 | 2016 | 19 | 0.130 |
Why?
| | Pyridines | 1 | 2019 | 425 | 0.130 |
Why?
| | Thrombosis | 1 | 2019 | 297 | 0.130 |
Why?
| | Academic Medical Centers | 3 | 2019 | 415 | 0.130 |
Why?
| | Pain Management | 1 | 2018 | 289 | 0.130 |
Why?
| | Antiviral Agents | 1 | 2021 | 647 | 0.130 |
Why?
| | Aged, 80 and over | 5 | 2018 | 6364 | 0.120 |
Why?
| | Therapeutics | 1 | 2015 | 12 | 0.120 |
Why?
| | Methanol | 1 | 2015 | 29 | 0.120 |
Why?
| | Peptic Ulcer Hemorrhage | 1 | 2014 | 6 | 0.120 |
Why?
| | Cardiopulmonary Bypass | 1 | 2016 | 176 | 0.120 |
Why?
| | beta-Cyclodextrins | 1 | 2015 | 28 | 0.120 |
Why?
| | Multivariate Analysis | 3 | 2017 | 1440 | 0.120 |
Why?
| | Placebo Effect | 1 | 2015 | 51 | 0.120 |
Why?
| | Practice Guidelines as Topic | 4 | 2015 | 1400 | 0.120 |
Why?
| | Vasodilator Agents | 1 | 2016 | 305 | 0.120 |
Why?
| | Acute Disease | 3 | 2008 | 915 | 0.120 |
Why?
| | Shivering | 1 | 2013 | 4 | 0.110 |
Why?
| | Stress Disorders, Traumatic, Acute | 1 | 2013 | 7 | 0.110 |
Why?
| | Osmotic Pressure | 1 | 2014 | 28 | 0.110 |
Why?
| | Medicare | 2 | 2009 | 666 | 0.110 |
Why?
| | Liver Diseases | 1 | 2016 | 254 | 0.110 |
Why?
| | Benzodiazepines | 1 | 2014 | 116 | 0.110 |
Why?
| | Pneumonia, Ventilator-Associated | 1 | 2014 | 40 | 0.110 |
Why?
| | Gene Expression | 1 | 2018 | 1422 | 0.110 |
Why?
| | Hemostasis | 2 | 2019 | 67 | 0.110 |
Why?
| | Neurologic Examination | 1 | 2013 | 114 | 0.110 |
Why?
| | Thrombocytopenia | 3 | 2018 | 177 | 0.110 |
Why?
| | Drug Storage | 1 | 2013 | 59 | 0.110 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2013 | 125 | 0.110 |
Why?
| | Drug Stability | 1 | 2013 | 151 | 0.110 |
Why?
| | Drug Packaging | 1 | 2013 | 43 | 0.110 |
Why?
| | Administration, Oral | 4 | 2017 | 731 | 0.110 |
Why?
| | Propensity Score | 1 | 2014 | 224 | 0.110 |
Why?
| | Injections | 1 | 2013 | 159 | 0.110 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2013 | 162 | 0.110 |
Why?
| | Health Care Surveys | 1 | 2014 | 539 | 0.100 |
Why?
| | Clinical Trials as Topic | 2 | 2009 | 934 | 0.100 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 2 | 2023 | 243 | 0.100 |
Why?
| | Motilin | 1 | 2011 | 2 | 0.100 |
Why?
| | Cholecystokinin | 1 | 2011 | 15 | 0.100 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2013 | 474 | 0.100 |
Why?
| | RNA, Messenger | 1 | 2018 | 2559 | 0.100 |
Why?
| | Renal Dialysis | 1 | 2015 | 369 | 0.090 |
Why?
| | Mice, Inbred C57BL | 2 | 2018 | 4719 | 0.090 |
Why?
| | Respiratory Aspiration | 1 | 2011 | 31 | 0.090 |
Why?
| | Tandem Mass Spectrometry | 1 | 2013 | 413 | 0.090 |
Why?
| | Societies, Pharmaceutical | 2 | 2020 | 27 | 0.090 |
Why?
| | Drug Administration Schedule | 4 | 2018 | 718 | 0.090 |
Why?
| | Drug Resistance, Multiple | 1 | 2010 | 19 | 0.090 |
Why?
| | Severity of Illness Index | 2 | 2015 | 2542 | 0.090 |
Why?
| | Databases, Factual | 2 | 2018 | 1125 | 0.090 |
Why?
| | Lactoferrin | 1 | 2010 | 28 | 0.090 |
Why?
| | Contraindications | 1 | 2010 | 85 | 0.090 |
Why?
| | Hospitals, University | 2 | 2008 | 171 | 0.090 |
Why?
| | Kidney Failure, Chronic | 1 | 2015 | 488 | 0.080 |
Why?
| | Disease Models, Animal | 1 | 2018 | 3549 | 0.080 |
Why?
| | Hypoglycemia | 1 | 2013 | 386 | 0.080 |
Why?
| | Imipenem | 2 | 2010 | 16 | 0.080 |
Why?
| | Patient Care Team | 1 | 2013 | 516 | 0.080 |
Why?
| | Pilot Projects | 1 | 2013 | 1372 | 0.080 |
Why?
| | Multiple Organ Failure | 1 | 2010 | 142 | 0.080 |
Why?
| | Observer Variation | 1 | 2010 | 297 | 0.080 |
Why?
| | Diagnostic Errors | 1 | 2010 | 151 | 0.080 |
Why?
| | Quality Improvement | 3 | 2020 | 954 | 0.080 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2010 | 125 | 0.080 |
Why?
| | Treatment Failure | 1 | 2009 | 332 | 0.080 |
Why?
| | Adolescent | 5 | 2018 | 17829 | 0.080 |
Why?
| | Data Interpretation, Statistical | 1 | 2010 | 323 | 0.080 |
Why?
| | Blood Pressure | 2 | 2004 | 1537 | 0.080 |
Why?
| | Biomarkers | 2 | 2015 | 3418 | 0.080 |
Why?
| | Vitamin K | 1 | 2007 | 42 | 0.070 |
Why?
| | Anxiety | 1 | 2013 | 846 | 0.070 |
Why?
| | Databases as Topic | 1 | 2007 | 63 | 0.070 |
Why?
| | Phosphorus | 1 | 2007 | 81 | 0.070 |
Why?
| | Magnesium | 1 | 2007 | 145 | 0.070 |
Why?
| | Potassium | 1 | 2007 | 128 | 0.070 |
Why?
| | Burn Units | 1 | 2007 | 26 | 0.070 |
Why?
| | Antihypertensive Agents | 1 | 2010 | 429 | 0.070 |
Why?
| | Cerebral Hemorrhage | 1 | 2007 | 96 | 0.070 |
Why?
| | Cost Control | 1 | 2006 | 38 | 0.070 |
Why?
| | Cellulitis | 1 | 2007 | 45 | 0.070 |
Why?
| | Societies, Medical | 2 | 2020 | 677 | 0.070 |
Why?
| | Intraoperative Complications | 1 | 2007 | 122 | 0.070 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2011 | 1134 | 0.070 |
Why?
| | Kidney Diseases | 1 | 2009 | 350 | 0.070 |
Why?
| | Economics, Pharmaceutical | 1 | 2005 | 10 | 0.060 |
Why?
| | Pipecolic Acids | 1 | 2005 | 23 | 0.060 |
Why?
| | Fibrinolysis | 1 | 2007 | 158 | 0.060 |
Why?
| | Depression | 1 | 2013 | 1134 | 0.060 |
Why?
| | Risk Assessment | 1 | 2014 | 2975 | 0.060 |
Why?
| | Arginine Vasopressin | 1 | 2005 | 46 | 0.060 |
Why?
| | Octreotide | 1 | 2005 | 25 | 0.060 |
Why?
| | Case-Control Studies | 2 | 2014 | 3008 | 0.060 |
Why?
| | Neoplasms | 1 | 2018 | 2106 | 0.060 |
Why?
| | Blood Component Transfusion | 1 | 2005 | 75 | 0.060 |
Why?
| | Costs and Cost Analysis | 1 | 2005 | 195 | 0.060 |
Why?
| | Quality-Adjusted Life Years | 1 | 2005 | 101 | 0.060 |
Why?
| | beta-Lactam Resistance | 1 | 2004 | 6 | 0.060 |
Why?
| | Ceftazidime | 1 | 2004 | 5 | 0.060 |
Why?
| | Animals | 4 | 2018 | 31839 | 0.060 |
Why?
| | Ciprofloxacin | 1 | 2004 | 23 | 0.060 |
Why?
| | Sex Factors | 1 | 2009 | 1721 | 0.060 |
Why?
| | Tobramycin | 1 | 2004 | 47 | 0.060 |
Why?
| | Urine | 1 | 2004 | 55 | 0.060 |
Why?
| | Sentinel Surveillance | 1 | 2004 | 38 | 0.060 |
Why?
| | Hospitals, Teaching | 1 | 2004 | 102 | 0.060 |
Why?
| | Hospitals, Urban | 1 | 2004 | 127 | 0.060 |
Why?
| | Models, Biological | 1 | 2010 | 1630 | 0.050 |
Why?
| | Skin Diseases | 1 | 2004 | 122 | 0.050 |
Why?
| | Liver Transplantation | 1 | 2009 | 706 | 0.050 |
Why?
| | Age Factors | 1 | 2009 | 2891 | 0.050 |
Why?
| | Hospital Mortality | 1 | 2007 | 776 | 0.050 |
Why?
| | Adrenal Cortex | 1 | 2002 | 32 | 0.050 |
Why?
| | Reproducibility of Results | 1 | 2010 | 2770 | 0.050 |
Why?
| | Hypertension | 1 | 2010 | 1059 | 0.050 |
Why?
| | Pneumonia, Bacterial | 1 | 2003 | 106 | 0.050 |
Why?
| | Hospitals | 1 | 2006 | 581 | 0.050 |
Why?
| | Gastric Mucosa | 1 | 2000 | 46 | 0.050 |
Why?
| | Gastrointestinal Motility | 1 | 2000 | 25 | 0.050 |
Why?
| | Heart Rate | 1 | 2004 | 705 | 0.050 |
Why?
| | Stomach | 1 | 2000 | 101 | 0.040 |
Why?
| | Therapeutic Index | 1 | 2020 | 2 | 0.040 |
Why?
| | Cost Savings | 1 | 2000 | 74 | 0.040 |
Why?
| | Intestinal Absorption | 1 | 2000 | 93 | 0.040 |
Why?
| | Placebos | 1 | 2000 | 198 | 0.040 |
Why?
| | Cross-Over Studies | 1 | 2000 | 441 | 0.040 |
Why?
| | Child | 1 | 2017 | 18366 | 0.040 |
Why?
| | Comparative Effectiveness Research | 1 | 2018 | 130 | 0.040 |
Why?
| | Parenteral Nutrition, Total | 1 | 1997 | 27 | 0.040 |
Why?
| | Administration, Intravenous | 1 | 2017 | 125 | 0.040 |
Why?
| | Emergency Service, Hospital | 1 | 2007 | 1813 | 0.030 |
Why?
| | Crohn Disease | 1 | 1997 | 196 | 0.030 |
Why?
| | Seizures | 1 | 2017 | 340 | 0.030 |
Why?
| | Standard of Care | 1 | 2014 | 62 | 0.030 |
Why?
| | Acidosis | 1 | 2015 | 87 | 0.030 |
Why?
| | Young Adult | 2 | 2019 | 10478 | 0.030 |
Why?
| | Rats | 1 | 2001 | 4963 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2014 | 333 | 0.030 |
Why?
| | Canada | 1 | 2014 | 322 | 0.030 |
Why?
| | Logistic Models | 1 | 2017 | 1844 | 0.030 |
Why?
| | Risk | 1 | 2014 | 815 | 0.020 |
Why?
| | Antithrombins | 1 | 2010 | 49 | 0.020 |
Why?
| | Genes, Regulator | 1 | 2010 | 34 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2010 | 319 | 0.020 |
Why?
| | Microcirculation | 1 | 2010 | 135 | 0.020 |
Why?
| | Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2009 | 38 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 1997 | 2326 | 0.020 |
Why?
| | Liver Cirrhosis | 1 | 2009 | 228 | 0.020 |
Why?
| | Drug Costs | 1 | 2008 | 91 | 0.020 |
Why?
| | Drug Utilization | 1 | 2008 | 167 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2010 | 1153 | 0.020 |
Why?
| | Inpatients | 1 | 2010 | 380 | 0.020 |
Why?
| | Thienamycins | 1 | 2005 | 4 | 0.020 |
Why?
| | Colistin | 1 | 2005 | 8 | 0.020 |
Why?
| | Polymyxin B | 1 | 2005 | 21 | 0.020 |
Why?
| | Antidiuretic Agents | 1 | 2005 | 7 | 0.020 |
Why?
| | Hospitalization | 1 | 2014 | 1754 | 0.020 |
Why?
| | Platelet Activation | 1 | 2005 | 68 | 0.020 |
Why?
| | Platelet Aggregation | 1 | 2005 | 94 | 0.020 |
Why?
| | Endothelial Cells | 1 | 2010 | 685 | 0.020 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2004 | 63 | 0.010 |
Why?
| | Arginine | 1 | 2005 | 237 | 0.010 |
Why?
| | Guideline Adherence | 1 | 2008 | 490 | 0.010 |
Why?
| | Cardiac Surgical Procedures | 1 | 2008 | 414 | 0.010 |
Why?
| | Kidney Transplantation | 1 | 2009 | 542 | 0.010 |
Why?
| | DNA | 1 | 2010 | 1351 | 0.010 |
Why?
| | Algorithms | 1 | 2010 | 1474 | 0.010 |
Why?
| | Drug Resistance, Microbial | 1 | 2003 | 67 | 0.010 |
Why?
| | Transcription Factors | 1 | 2010 | 1530 | 0.010 |
Why?
| | Sulfonamides | 1 | 2005 | 445 | 0.010 |
Why?
| | Liver | 1 | 2010 | 1634 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2010 | 4427 | 0.010 |
Why?
| | Population Surveillance | 1 | 2004 | 392 | 0.010 |
Why?
| | Mutation | 1 | 2010 | 3354 | 0.010 |
Why?
| | Mice | 1 | 2010 | 14936 | 0.010 |
Why?
|
|
MacLaren's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|